Meeting
2017 ASCO Annual Meeting
Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for Neuroendocrine Prostate Cancer (NEPC).
Authors
Loredana Puca
Weill Cornell Medical College, New York, NY
Loredana Puca , Verena Sailer , Kaitlyn Gayvert , Kumiko Isse , Michael Sigouros , David M. Nanus , Scott T. Tagawa , Juan Miguel Mosquera , Laura Saunders , Himisha Beltran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5029)
DOI
10.1200/JCO.2017.35.15_suppl.5029
Abstract #
5029
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Genomic analysis and prediction of therapeutic vulnerabilities of small cell lung cancer from rovalpituzumab tesirine phase III trial (MERU).
First Author: Weilong Zhao
Poster
2023 ASCO Genitourinary Cancers Symposium
Identification of lineage-specific transcription factor defined subtypes in small cell/neuroendocrine bladder cancer.
First Author: Woonyoung Choi
Poster
2022 ASCO Annual Meeting
Genomic alterations and evolution in patients with prostate cancer with histologic evidence of neuroendocrine differentiation.
First Author: Ethan Barnett
Poster
2022 ASCO Annual Meeting
Molecular correlates of Delta-like-ligand 3 (DLL3) expression in neuroendocrine neoplasms (NENs).
First Author: Justin Hwang